Ultragenyx Pharmaceutical Inc. RARE
17.16 USD +0.53 (+3.19%)
At closeNov 5, 2026, 4:00 AM EST
16.98 -0.18 -1.05%
Pre-market · Nov 5, 4:00 AM ET
16.23 Day range 17.67
12.73 52-week range 39.89
- YTD
- -25.39%
- 1 year
- -47.13%
News
benzinga.com Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $34 Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $39 to $34.
benzinga.com TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $19 TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $18 to $19.
benzinga.com Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $22 Morgan Stanley analyst Maxwell Skor maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Equal-Weight and raises the price target from $20 to $22.- benzinga.com Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $17 Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $19 to $17.
seekingalpha.com Ultragenyx: Still Lacking Appeal Despite 'Commercial-First' Pivot Ultragenyx Pharmaceutical remains a cautious 'Hold,' as profitability targets are driven by deep R&D cuts, not robust revenue growth. RARE's Q3 revenue rose 8% Y/Y to $173M, but business remains…- benzinga.com Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $22 Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $25 to $22.
benzinga.com Ultragenyx Pushes Toward Profitability in 2027, Led by Pruned Pipeline, Layoffs Ultragenyx cuts 20% of staff and trims pipeline programs after missing Q3 targets, aiming for 2027 profitability through new commercial launches.
benzinga.com Amdocs Posts Downbeat Q4 Earnings, Joins Skyworks Solutions, Tesla And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures rose, while Amdocs plunged 39% after missing Q4 estimates and issuing weak FY27 guidance; several other stocks also fell premarket.
seekingalpha.com Ultragenyx Pharmaceutical Inc. (RARE) Q3 2026 Earnings Call Transcript Ultragenyx Pharmaceutical Inc. ( RARE ) Q3 2026 Earnings Call November 3, 2026 5:00 PM EST Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis -…
marketbeat.com What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call Ultragenyx Pharmaceutical NASDAQ: RARE said its third quarter included two U.S. gene therapy approvals, a failed late-stage Angelman syndrome study, the termination of its Wilson disease program and…
zacks.com Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates Ultragenyx (RARE) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $1.81 per share a year ago.
zacks.com Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics…
benzinga.com Ultragenyx Pharmaceutical Q3 2026 Earnings Call Transcript Ultragenyx Pharmaceutical (NASDAQ:RARE) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Ultragenyx Pharmaceutical Announces UX701 AAV9 Gene Therapy To Treat Wilson Disease Failed To Meet Criteria, Being Terminated Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today…
benzinga.com Ultragenyx Pharmaceutical Eliminating ~20% Employees Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Nordicus Partners (NASDAQ:NORD) stock increased by 10.8% to $4.5 during Tuesday's after-market session. The market value of their outstanding shares is at $71.5 million. Gelteq (NASDAQ:GELS)…- benzinga.com Ultragenyx Pharmaceutical Affirms FY2026 Sales Guidance of $730.000M-$760.000M vs $762.256M Est Ultragenyx Pharmaceutical (NASDAQ:RARE) affirms FY2026 sales outlook from $730.000 million-$760.000 million to $730.000 million-$760.000 million vs $762.256 million estimate.
- benzinga.com Ultragenyx Pharmaceutical Q3 EPS $(1.16) Misses $(1.12) Estimate, Sales $173.000M Miss $183.118M Estimate Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(1.12) by 3.57 percent. This is a 35.91 percent increase over…
globenewswire.com Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027 Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter Two Priority Review…
benzinga.com Ultragenyx Settles DOJOLVI Patent Litigation With Navinta, Allowing Generic Entry Starting January 1, 2033; Or July 2033 With Pediatric Exclusivity; Similar Patent Litigation Against Other DOJOLVI Abbreviated New Drug Application Filers Related To DOJOLVI Remains Pending On October 19, 2026, Ultragenyx Pharmaceutical Inc. (the "Company") and Baylor Research Institute ("BRI") entered into a settlement agreement with Navinta LLC ("Navinta") resolving patent- benzinga.com UBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16 UBS analyst Joon Lee initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral rating and announces Price Target of $16.
- benzinga.com Ultragenyx Pharmaceutical Inks $210M Deal To Sell Rare Pediatric Disease Priority Review Voucher Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million.…